Atlas Trials

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Clinical trial NCT02608268 · TERMINATED

Trial details

NCT number
NCT02608268
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced Malignancies
Start date
2015-11-23
Primary completion
2022-08-30
Enrollment
252

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.